Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 111 |
| Active Pipeline (Recruiting Now) | 85 (53) |
| Completed vs Stopped Early | 9 / 16 (14.4%) |
| Median Closed Actual Enrollment | 26 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| City of Hope National Medical Center | Duarte, CA | 105 |
| City of Hope Orange County | Irvine, CA | 21 |
| City of Hope (South Pasadena) | South Pasadena, CA | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05751434 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | Phase II | RECRUITING |
| NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lympho | Phase II | RECRUITING |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV N | Phase II | RECRUITING |
| NCT03712202 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | Phase II | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for City of Hope across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the City of Hope Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.